Interactions with the extracellular matrix (ECM) through integrin adhesion receptors provide cancer cells with physical and chemical cues that act together with growth factors to support survival and proliferation. Antagonists that target integrins containing the b 1 subunit inhibit tumor growth and sensitize cells to irradiation or cytotoxic chemotherapy in preclinical breast cancer models and are under clinical investigation. We found that the loss of b 1 integrins attenuated breast tumor growth but markedly enhanced tumor cell dissemination to the lungs. When cultured in three-dimensional ECM scaffolds, antibodies that blocked b 1 integrin function or knockdown of b 1 switched the migratory behavior of human and mouse E-cadherin-positive triple-negative breast cancer (TNBC) cells from collective to single cell movement. This switch involved activation of the transforming growth factor-b (TGFb) signaling network that led to a shift in the balance between miR-200 microRNAs and the transcription factor zinc finger E-box-binding homeobox 2 (ZEB2), resulting in suppressed transcription of the gene encoding E-cadherin. Reducing the abundance of a TGFb receptor, restoring the ZEB/miR-200 balance, or increasing the abundance of E-cadherin reestablished cohesion in b 1 integrin-deficient cells and reduced dissemination to the lungs without affecting growth of the primary tumor. These findings reveal that b 1 integrins control a signaling network that promotes an epithelial phenotype and suppresses dissemination and indicate that targeting b 1 integrins may have undesirable effects in TNBC.
INTRODUCTION
The cell-cell adhesion receptor E-cadherin is an established suppressor of cell invasion (1, 2) . Yet, highly aggressive tumors, including infiltrating ductal breast carcinomas, metastasize in its apparent presence (3) . In such cancers, a transient loss of E-cadherin during local epithelial-to-mesenchymal transitions (EMT) is believed to promote tumor dissemination (4) . The reverse process, MET, may promote subsequent clonal outgrowth of disseminated tumor cells at metastatic sites (5) . The balance between EMT and MET is controlled by transforming growth factor-b (TGFb) signaling through a double-negative feed-forward interaction between the microRNA (miR)-200 family and zinc finger E-box-binding homeobox (ZEB) transcriptional repressors targeting CDH1 transcripts, encoding E-cadherin (6) (7) (8) . Thus, understanding how alterations in this network are triggered in tumor cells is critical to improving strategies to treat or prevent metastatic disease.
Integrins, another class of adhesion receptors, mediate adhesion to extracellular matrix (ECM) proteins and promote cell survival and proliferation (9, 10) . Hence, drugs that disrupt integrin-mediated adhesion of cancer cells or cells in the tumor microenvironment, including endothelial cells, are under clinical investigation (11, 12) . Antibody blocking and gene deletion in mouse models suggest that members of the b 1 subfamily of integrins represent therapeutic targets in breast cancer (13) (14) (15) (16) . However, correlations of b 1 integrin abundance with cancer progression or patient survival are ambiguous, and data obtained in some mouse models for breast or prostate cancer indicate that b 1 integrins may, in fact, suppress cancer progression (13, (17) (18) (19) .
Integrins also control cell migration on two-dimensional (2D) ECM surfaces or within 3D ECM scaffolds (20) (21) (22) (23) . Thus, integrin-mediated ECM contacts influence multiple aspects of tumor cell biology ranging from survival to proliferation to migration. This occurs through modulation of various signaling networks (24) (25) (26) (27) that are rewired by mutations that differ between cancer types and patients. Hence, the consequence of altered integrin expression profiles as observed with cancer progression (18) or the effect of integrin-targeted therapies may be highly context-dependent. Here, we find that loss of b 1 integrins has remarkably distinct effects on tumor growth versus migration, dissemination, and metastasis in the context of E-cadherinpositive triple-negative breast cancer (TNBC), indicating that the use of b 1 integrins as drug targets may need reconsideration.
receptor, and human epidermal growth factor receptor 2), E-cadherinpositive 4T1 cells injected into the mammary fat pad. Knockdown of b 1 integrins using two distinct short hairpin RNAs (shRNAs) in this model (4T1-shb 1 ) suppressed the outgrowth within the mammary gland compared with tumors derived from wild-type or control shRNA-transduced cells (Fig. 1, A and B ). However, tumors in which b 1 integrins were silenced showed a marked increase in the number of lung colonies, indicating that tumor growth and metastatic potential were inversely affected (Fig. 1C) . Like the primary tumor, lung metastases that originated from 4T1-shb 1 tumors were smaller than those derived from control tumors (Fig. 1C) . The number of circulating tumor cells produced by the small b 1 integrindepleted tumors detected 3 to 4 weeks after implantation was also significantly increased ( Fig. 1D) . As in mice, knockdown of b 1 integrins increased the ability of 4T1 cells to migrate away from the primary tumor cell mass in xenografts ( Fig. 1 , E and F), in which tumor cells were injected into the yolk of zebrafish embryos and monitored for distance traveled throughout the embryo (28) . Thus, a suppressive role of b 1 integrins in tumor cell dissemination was observed in two in vivo models. Disruption of b 1 integrin-mediated adhesion triggers a switch from collective invasion to individual cell migration in mouse and human E-cadherin-positive TNBC
On the basis of these in vivo results, we asked how the loss of b 1 integrins affected cell migration strategies. We noticed that b 1 integrindepleted 4T1 cells lost cell-cell contacts and displayed a scattered morphology in 2D culture ( Fig. 2A ). This effect was reversible: Reexpression of b 1 integrins fully restored cellcell contacts and island formation ( Fig. 2A) . Tumor cell spheroids were generated in 3D collagen ECM scaffolds, as previously described, to assess cell migration in 3D culture (34) . Under these conditions, 4T1 cells displayed collective invasion, with E-cadherin-positive cell-cell contacts remaining intact ( Fig. 2B and movie S1). Silencing b 1 integrins in 4T1 cells blocked collective invasion and triggered a switch to effective single-cell migration (Fig. 2C, fig.  S1 , and movie S2). Treatment of 4T1 cells with a function-blocking antibody against b 1 integrin also prevented collective invasion and promoted individual cell migration ( Fig. 2D and fig. S1 ). Moreover, an identical switch after b 1 integrin inhibition was observed in BT20 human E-cadherin-positive TNBC cells. Again, decreased abundance of b 1 integrins induced a shift from invasive outgrowth to the migration of individual cells (Fig. 2 , C and E, and fig. S1 ). Collective invasion of MCF10A nontumorigenic breast epithelial cells was also blocked in response to b 1 integrin silencing, but these cells were unable to switch their migration strategy, and, instead, motility was arrested. MDA-MB-435S E-cadherin-negative TNBC cells already migrated as individual cells, and the inhibition of b 1 integrins in these cells had little effect, other than inducing a more rounded morphology (Fig. 2 , C and E), which is in agreement with other reports indicating that mesenchymal, but not amoeboid, individual cell movement depends on integrin-mediated ECM attachments (21) . Together, these findings indicate that E-cadherin-positive TNBC cells can effectively bypass the inhibition of collective invasion when ECM contacts through b 1 integrins are lost by switching their migration strategy to individual cell migration.
Knockdown of b 1 integrins triggers a loss of E-cadherin, which is critical for the prometastatic switch in cell migration
To analyze the signal rewiring that is induced by the loss of b 1 integrin, we compared gene expression profiles of two independent shb 1 lines with wild-type and shRNA-treated control 4T1 cells. With a false discovery rate (FDR) <0.001 and 1.5-fold difference as a cutoff, 1230 differentially expressed genes were shared between both shb 1 lines (table S1). In this set, ingenuity pathway analysis predicted "cellular movement" as the process most significantly affected by b 1 integrin silencing and also predicted "cell-to-cell signaling." These processes showed a significant decrease in the expression of the Cdh1 gene, encoding E-cadherin, in the shb 1 -treated lines ( fig. S2 ).
Quantitative polymerase chain reaction (qPCR) analysis confirmed the decrease in Cdh1 transcript abundance, and, in agreement, about 75% less E-cadherin was detected on the cell surface of 4T1-shb 1 cells (Fig. 3 
and B)
. Likewise, silencing b 1 integrins in BT20 cells strongly suppressed the abundance of E-cadherin mRNA and cell surface protein (Fig. 3, A and B). Silencing b 1 integrins also diminished total E-cadherin protein abundance in 4T1 and BT20 cells (Fig. 3C) . The connection between b 1 integrins and E-cadherin abundance was further confirmed in two other human TNBC cell lines, MDA-MB-468 and HCC1806 (Fig. 3D) . Decreased E-cadherin abundance in response to the knockdown of b 1 integrins was also observed in vivo: E-cadherin staining in cell-cell contacts in primary tumors derived from 4T1-shb 1 cells was markedly reduced as compared to that in control tumors (Fig. 3E) . Finally, in agreement with reversibility of the cell scattering phenotype ( Fig. 2A) , reexpression of b 1 integrins restored the surface abundance of E-cadherin in 4T1-shb 1 cells (Fig. 3F) .
We next tested if the reduction in E-cadherin abundance was critically involved in the prometastatic switch in cell migration strategy triggered by b 1 integrin loss. In support of this, ectopic expression of E-cadherin in 4T1-shb 1 cells at a similar surface abundance as that in controls restored cell-cell adhesion and collective invasion (Fig. 4 , A and B, and fig. S1 ). Ectopic E-cadherin expression also blocked the enhanced ability of 4T1-shb 1 tumors to metastasize to the lungs (Fig.  4C) . Conversely, silencing E-cadherin in wild-type 4T1 cells (4T1-shCdh1) decreased cell cohesion and induced the migration of single, elongated cells into collagen (Fig. 4 , A and B). However, in vivo, the number of lung colonies produced by 4T1-shCdh1 cells was similar to that observed for wild-type 4T1 cells (Fig. 4C ). These data indicate that the reduction in E-cadherin is essential for the prometastatic switch in the cell migration strategy triggered by b 1 integrin inhibition, but that it is not sufficient by itself to increase metastatic spread. Moreover, tumor growth was not affected by E-cadherin knockdown and was suppressed in response to b 1 integrin silencing, irrespective of the absence or presence of E-cadherin, further demonstrating that b 1 integrins control tumor growth and metastasis through separate pathways (Fig. 4D ).
Enhanced ZEB2 expression in response to knockdown of b 1 integrins blocks Cdh1 transcription and causes enhanced metastasis
Having established a connection between b 1 integrins and E-cadherin abundance that critically affects metastatic behavior, we investigated the mechanism by which loss of b 1 integrin-mediated ECM attachment triggers a block in Cdh1 expression. Luciferase reporter assays showed that b 1 integrin silencing decreased transcription from the Cdh1 gene by about 80% (Fig. 5A ). This prompted us to investigate the b 1 integrin-associated regulation of a group of E-cadherin transcriptional repressors, including members of the Snail, basic helix-loop-helix (bHLH), and zinc finger homeodomain (ZFH) families that are implicated in EMT (4). Analysis of the microarray data showed that of these repressors, only the expression of the gene encoding ZEB2 (also known as Sip1) was significantly increased in both 4T1-shb 1 lines ( fig. S2 ). qPCR analysis confirmed the induction of ZEB2 expression upon b 1 integrin silencing in 4T1 cells and showed a similar, albeit more marked, induction of ZEB2 in BT20 cells (Fig. 5 , B and C).
To test if the increase in ZEB2 expression was implicated in blocking Cdh1 transcription and enhancing metastatic capacity triggered by b 1 integrin loss, we generated b 1 integrin and ZEB2 double-knockdown 4T1 cells using each of three shRNAs against ZEB2 (Fig. 5D ). All three independent shRNA lines showed that reverting the enhanced ZEB2 expression in b 1 integrin-depleted cells restored Cdh1 expression to the same degree or higher than that observed in wild-type cells (Fig. 5D ). As observed with E-cadherin reexpression (Fig. 4D) , silencing ZEB2 did not affect the reduced growth of 4T1-shb 1 tumors (Fig. 5E ). However, again in good agreement with the E-cadherin rescue experiment (Fig. 4C) , two independent ZEB2 shRNAs blocked the enhanced metastasis of b 1 integrin-depleted cells (Fig. 5F ). Together, these data indicate that the transcriptional repression of Cdh1 induced by b 1 integrin loss is mediated by activation of ZEB2, and further support that loss of b 1 integrins affects tumor growth and metastasis through different pathways.
Alterations in the balance between ZEB and miR-200 after the loss of b 1 integrins cause E-cadherin suppression and a switch from collective invasion to single-cell migration ZEB transcription factors and miR-200 miRNAs establish a negative feedforward loop that is implicated in EMT, and alterations in the balance between ZEB and miR-200 may underlie progression of a number of different types of cancer, including breast carcinomas (6, 7). We assessed how (Fig. 6D) . Together, these findings demonstrate that the loss of b 1 integrins triggers a shift in the balance between ZEB and miR-200 family members, which induces a decrease in E-cadherin and a prometastatic switch from collective invasion to single-cell migration.
Alterations in the TGFb signaling network drive the prometastatic switch induced by b 1 integrin down-regulation Increased TGFb signaling has been implicated in the dissemination of subsets of individually migrating cells from breast tumors (35) . Autocrine TGFb signaling can stabilize an EMT phenotype through the repression of miR-200 (8), but it is not known what may trigger local TGFb signaling to induce EMT-like changes and dissemination. The findings described thus far suggested that disruption of b 1 integrin-mediated cell adhesion might represent one such trigger. Indeed, examination of the 1230 differentially expressed genes that were shared between both 4T1-shb 1 lines identified alterations in genes encoding proteins in the TGFb signaling or the related bone morphogenetic protein (BMP) signaling pathway (table S1 and Fig. 7A ). qPCR analysis verified these events and demonstrated that several of the changes (such as increased expression of the gene encoding Smad6 or decreased expression of genes encoding inhibin and BMP7) were similarly observed in BT20 cells after b 1 integrin knockdown (Fig. 7B) . We used immunostaining of phosphorylated Smad2 and 3 (p-Smad2/3) to assess basal TGFb signaling. Nuclear staining of p-Smad2/3 was significantly increased in response to b 1 integrin knockdown, indicating increased TGFb signaling in these cells (Fig. 7C) . We next tested if such increased TGFb signaling could explain the decreased Cdh1 transcription and the enhanced metastatic capacity triggered by b 1 integrin loss. For this purpose, the enhanced expression of the gene encoding TGFb receptor 3 (TGFbR3; also known as betaglycan) identified by gene expression profiling and verified by qPCR analysis (table S1 and Fig. 7D ) was blocked by targeted shRNA. Two independent TGFbR3 shRNAs restored Cdh1 expression in 4T1-shb 1 cells (Fig. 7D) . This was accompanied by a restored capacity of the cells to form islands in 2D culture (Fig. 7E) . Moreover, interfering with the enhanced abundance of TGFbR3 also prevented the enhanced lung metastasis seen in b 1 integrin-depleted cells, whereas tumor growth remained suppressed (Fig. 7, F and G) . Thus, interfering with alterations in the TGFb/BMP signaling network at the level of TGFbR3 phenocopied the effects of ZEB2 inhibition or E-cadherin reexpression by restoring epithelial characteristics and mitigating enhanced metastasis in b 1 integrin-depleted cells. Together, these results indicate that disruption of b 1 integrin-mediated cell adhesion can trigger alterations in the TGFb signaling network that drive EMT-like changes and increased dissemination in TNBC.
DISCUSSION
This study demonstrates that b 1 integrinmediated cell-ECM interactions support orthotopic breast cancer growth but that inhibition of b 1 integrins can trigger a rewiring of signaling pathways that lead to enhanced metastatic spread in TNBC (Fig. 8) .
The role of b 1 integrin-mediated ECM attachments in tumor growth agrees with earlier studies (10, 13, 14) . Moreover, the smaller size of lung metastases produced from the b 1 integrin-depleted tumors indicates that, besides primary tumor growth, b 1 integrins also support outgrowth of metastatic colonies in the lung. This confirms and extends earlier reports where outgrowth of breast cancer cells arrested in the lung after intravenous injection was also shown to require integrin signaling (36, 37) . Preclinical studies have implicated b 1 integrins in cancer initiation, growth, and progression, but correlations of b 1 integrin abundance with overall or metastasis-free patient survival are ambiguous, and in some mouse models for breast or prostate cancer, b 1 integrins, in fact, suppress cancer progression (10) (11) (12) (13) (14) (17) (18) (19) . Here, we show that b 1 integrin depletion can cause increased metastatic spread that is related to a marked switch in migration strategy of TNBC cells. The effect on cell migration is context-dependent. E-cadherin-negative cells that move as single cells are mildly affected by the disruption of ECM attachments, whereas tumor cell types that move as collective strands may either be arrested or undergo a prometastatic switch toward individual cell movement. Invasion of T4-2 cells derived from HMT-3522 breast epithelial cells in Matrigel (38) or invasion of MCF10A cells in collagen (Fig. 2C) is prevented when b 1 integrins are functionally blocked or knocked down. However, mouse and human E-cadherinpositive TNBC cells have sufficient plasticity to respond to b 1 integrin inhibition by switching to an alternative migration strategy through loss of cohesion, resulting in enhanced dissemination and lung colonization.
Whereas E-cadherin is almost invariably lost in invasive lobular breast carcinomas, its expression is retained in many other types including the common ductal invasive carcinomas (3). In those cases, changes in b 1 integrin abundance in a population of tumor cells may drive a local transient EMT-like switch. It remains to be studied whether disruption of ECM interactions, for instance, through altered proteolytic ECM degradation, can have similar consequences, but this is supported by our finding that b 1 antibodies can induce a similar migration switch. In agreement, previous work by us and others has shown that conditions that disturb ECM adhesion in 2D culture (39) or in 3D ECM matrices of low rigidity (34) can disrupt cell-cell contacts.
Integrin-mediated ECM adhesion can modulate cell-cell adhesion; both positive and negative regulations have been reported, but crosstalk at the level of E-cadherin (CDH1) expression has not been previously demonstrated (29, (38) (39) (40) (41) . EMT and loss of E-cadherin have been implicated in initiating the outgrowth of dormant metastatic breast cancer lesions through activation of pro-proliferative b 1 integrin-mediated signaling (42) . Conversely, although EMT may drive early steps of the metastatic cascade, the inverse process, MET is also shown to be critical for outgrowth of breast cancer metastases (5). Our findings indicate that suppressed outgrowth of b 1 integrin-depleted breast tumors or metastatic lesions was unrelated to the expression of E-cadherin and consequent cell cohesion. On the other hand, the switch from collective invasion to individual cell migration and enhanced dissemination to the lungs was fully dependent on the loss of E-cadherin. Thus, b 1 integrins control migration and growth during breast cancer progression through separate pathways.
TGFb is a key inducer of EMT, and autocrine TGFb signaling can stabilize an EMT phenotype by repressing miR-200 (8) . A transient increase in TGFb signaling has also been associated with the propensity of a subset of individually migrating cells in breast cancers to disseminate (35) . Our findings indicate that loss or disruption of b 1 integrin-mediated ECM adhesion may serve as one trigger for such local increased TGFb signaling, leading to EMT and enhanced dissemination. Certain integrins can activate latent TGFb, and effects of integrins on TGFbR expression have been reported (43) . Another study shows that b 3 integrins stimulate TGFb responsiveness in 4T1 cells after inactivation of b 1 integrins and are required for primary tumor growth and total lung tumor burden when b 1 integrins were knocked down (44) . Our observation of a strong negative selection against b 1 /b 3 cosilencing, precluding us to directly test a v b 3 dependency in our model, is in line with the notion that an increase in a v b 3 can compensate for the loss of b 1 to promote proliferation and tumor growth. In addition to its apparently critical role in stimulating growth, a v b 3 can stimulate TGFb signaling through its ability to bind the RGD (Arg-Gly-Asp) motif in the TGFb latency-associated protein, LAP (43) , and may well be involved in the prometastatic TGFb signaling-associated cascade triggered by the loss of b 1 integrin. However, enhanced expression of a v b 3 was not sufficient to drive this switch, thus placing responsibility with the suppressive activity of b 1 integrins. Our findings demonstrate that the inhibition of b 1 integrins can trigger extensive rewiring of the TGFb-controlled ZEB/miR-200 signaling network. The affected genes within this network are, to a large extent, shared between mouse 4T1 and human BT20 cells. We showed that restoring b 1 integrin expression or preventing the induction of ZEB2 or TGFbR3 reinstates Cdh1 expression and cell cohesion. Each of these strategies was also sufficient to block the increased dissemination capacity. ZEB2 forms a transcriptional control circuit with miR-200 members in breast cancer that regulates EMT and cancer stem cell characteristics (7, 8, 45) . The role of TGFbR3 in breast cancer appears to be highly dependent on other components of the network: TGFbR3 can either promote or interfere with TGFb and BMP signaling, for example, membrane-bound TGFbR3 can activate TGFbR1 and TGFbR2 through ligand presentation, whereas cleaved soluble TGFbR3 can sequester TGFb (46) . Moreover, TGFbR3 can mediate TGFb-induced EMT in some cases, but it is suppressed during TGFb-induced EMT in others (47) .
Together, our study demonstrates that the inhibition of b 1 integrins can rewire the TGFb/ZEB/miR-200 signaling network, driving loss of cohesion and increased dissemination of E-cadherin-positive TNBC cells. This process is fully reversible, and local alterations in b 1 integrin abundance or ECM-integrin crosstalk might represent one mechanism for a transient, TGFb-mediated EMT, enabling a subset of E-cadherin-positive breast cancer cells to disseminate to distant organs. These findings also raise concerns with respect to the use of b 1 integrins as drug targets to sensitize tumors to radio-or chemotherapy. Although tumor shrinkage is achieved and the growth of metastatic colonies is attenuated, in certain breast cancer types (E-cadherin-positive triple-negative variants), reprogramming of the surviving cells may aggravate metastatic spread.
MATERIALS AND METHODS

Cell lines and animals
4T1 mouse breast cancer cells, MCF10A human mammary epithelial cells, and BT20, MDA-MB-435S, MDA-MB-468, and HCC1806 human breast cancer cells were obtained from the American Type Culture Collection and cultured according to the provided protocol. Rag2
−/−
;gc −/− mice were housed in individually ventilated cages under sterile conditions. Housing and experiments were performed according to the Dutch guidelines for the care and use of laboratory animals. Sterilized food and water were provided ad libitum. Zebrafish were maintained according to standard protocols (http://ZFIN.org). Embryos were grown at 28.5°to 30°C in egg water (Instant Ocean salts, 60 mg/ml). During injection with tumor cells, embryos were kept under anesthesia in 0.02% buffered 3-aminobenzoic acid ethyl ester (tricaine; Sigma).
Antibodies
For FACS, primary antibodies were those against mouse integrin b 1 (HMb1-1; BD Pharmingen), human integrin b 1 (AIIB2; BD Transduction Laboratories), human E-cadherin (36/E-cadh; BD Transduction Laboratories), and mouse E-cadherin (DECMA; Sigma-Aldrich); secondary antibodies were allophycocyanin (APC)-conjugated anti-rat (Jackson ImmunoResearch Laboratories Inc.) and phycoerythrin (PE)-conjugated anti-mouse (Jackson ImmunoResearch Laboratories Inc.). For Western blotting, primary antibodies were those against mouse integrin b 1 and mouse or human E-cadherin (36/E-cadh; BD Transduction Laboratories), and a-tubulin (B-5-1-2; Sigma); secondary antibodies were horseradish peroxidase (HRP)-linked rabbit, rat, or mouse IgG (Jackson ImmunoResearch Laboratories Inc.). An antibody for integrin b 1 (HA2/5; BD Pharmingen) was used in function blocking studies. For immunohistochemistry, primary antibodies were those against mouse or human E-cadherin as for Western blotting and p-Smad2/3 (Cell Signaling Technology); secondary antibodies were Alexa 488-linked mouse IgG (Invitrogen) and Alexa 546-linked rabbit IgG (Invitrogen). F-actin was stained with Alexa 633 phalloidin (Molecular Probes).
shRNA, cDNA, and miRNA transfection Luciferase reporter assay 4T1 wild-type and 4T1-shb 1 cells were transiently transfected with 10 ng of an E-cadherin firefly luciferase reporter plasmid (provided by G. Berx, VIB, Gent, Belgium) (49) and 2 ng of a cytomegalovirus-Renilla luciferase reporter using Lipofectamine PLUS (Invitrogen) and analyzed using the Dual Luciferase Reporter Assay System (Promega) 3 days later, according to the manufacturer's procedures.
3D invasion assays
Tumor cell suspensions were injected into collagen type I gels, resulting in cell spheroids overnight as described (34) . Spheroids were monitored for 1 week. The number of single cells around spheroids at 3 days (4T1) or at 7 days (BT20) after injection was quantified using ImageJ. Edge detection and bandpass filter were used to remove background and noise, or background was subtracted from the image using a rolling ball filter. Subsequently, a mask was generated including collective invasion area, and single cells outside the mask were analyzed using automated thresholding for intensity and object size. Identification of single cells was verified manually for each image.
For immunostaining 4 days after injection, gels were incubated for 30 min with collagenase (5 mg/ml) (from Clostridium histolyticum; Boehringer Mannheim) at room temperature, fixed with 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked with 10% fetal bovine serum. Gels were incubated with rhodamine-conjugated phalloidin or with E-cadherin antibody followed by Alexa 488-conjugated secondary antibody and Hoechst nuclear staining. Preparations were mounted in Aqua-Poly/Mount solution (Polysciences Inc.) and analyzed using a Nikon TE2000 confocal microscope. Z-stacks (50 × 1 mm) were obtained using a 20× dry objective and converted into a single Z projection using the "extended depth of field" plug-in from ImageJ software.
For antibody blocking studies, cells were injected in collagen gels containing control IgG (10 mg/ml) or HA2/5 b 1 integrin antibody and overlaid with medium containing the same antibody concentrations.
For real-time imaging, about 3-hour time-lapse movies of spheroids were obtained starting at 48 hours after injection. Image acquisition was performed with a Nikon TE2000 confocal microscope with a temperature-and CO 2 -controlled incubator. Differential interference contrast time-lapse videos were recorded using a charged-coupled device camera controlled by NIS Elements software. Images were converted into a single AVI (audio video interleave) file in Image-Pro Plus (v5.1; Media Cybernetics). ). After 3 to 4 weeks, animals were anesthetized with pentobarbital, and primary tumor and lungs were excised. Primary tumor and left lung were divided into two pieces that were snap-frozen in liquid nitrogen for E-cadherin immunostaining or fixed in 4% paraformaldehyde for hematoxylin and eosin staining. To quantify lung metastases, right lungs were injected with ink solution, destained in water, and fixed in Feketes To analyze circulating tumor cells, blood was drawn from the right atrium of some mice by heart puncture after anesthetization but before excision of primary tumor and lungs. Blood (0.2 ml) was plated into 60-mm tissue culture dishes filled with growth medium. After 5 days, tumor cell clones were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) and counted with ImageJ.
Mouse orthotopic transplantation experiments
Zebrafish xenotransplantation experiments
CM-DiI-labeled tumor cells were transplanted into the yolk of dechorionated Fli-GFP transgenic zebrafish embryos, and after 6 days of incubation at 34°C, embryos were fixed and tumor cell dissemination was quantified by automated confocal imaging in 96-well plates followed by automated image analysis of Z-stacks as described (28) .
mRNA and miRNA analyses
For qPCR analysis of mRNA, RNAwas extracted using TRIzol (Invitrogen) and cDNA was randomly primed from 50 ng of total RNA using iScript cDNA Synthesis Kit (Bio-Rad). For detection of miRNAs, RNA was isolated using miRCURY RNA Isolation Kit (Cell & Plant), and cDNA was made using the Universal cDNA Synthesis Kit (Exiqon). Real-time qPCR was performed in triplicate using SYBR Green PCR (Applied Biosystems) on a 7900HT Fast Real-Time PCR System (Applied Biosystems). qPCR primers for mRNA are given in table S3; specific primers for miRNAs were obtained from Exiqon. qPCR data were collected and analyzed using SDS2.3 software (Applied Biosystems). Relative mRNA amounts after correction for b-actin control mRNA were expressed using 2 −DDCt method. For microarrays, total RNA was extracted using mirVana RNA Isolation Kit (Ambion Inc.). RNA quality and integrity were assessed with the 2100 Bioanalyzer system (Agilent Technologies). The Affymetrix 3′ IVT Express Labeling Kit was used to synthesize biotin-labeled complementary RNA, which was then hybridized to an Affymetrix MG-430 PM Array Plate. Data quality control was performed with Affymetrix Expression Console v1.1, and all raw data passed the Affymetrix quality criteria. Median normalization of raw expression data and identification of differentially expressed genes using a randomvariance t test were performed with BRB-ArrayTools Version 4.1.0 Beta 2 Release (developed by R. Simon and BRB-ArrayTools Development Team members; http://linus.nci.nih.gov/BRB-ArrayTools.html). Annotation was done according to the NetAffx annotation date release 2009-11-23. Corrections for multiple testing were performed as described by calculating the FDRs.
Western blot, flow cytometry, and immunohistochemistry
For Western blot, cells were lysed with modified radioimmunoprecipitation assay buffer [150 mM NaCl, 1.0% Triton X-100, 0.5% Na deoxycholate, 0.1% 50 mM tris (pH 8), and protease cocktail inhibitor (Sigma-Aldrich)]. Samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore), incubated with primary antibodies then HRP-labeled secondary antibodies (Jackson ImmunoResearch Laboratories Inc.), and developed with enhanced chemiluminescence substrate mixture (ECL Plus, Amersham, GE Healthcare). Blots were scanned on a Typhoon 9400 (GE Healthcare).
For FACS, cells were detached either with trypsin/EDTA (in the case of integrin surface expression) or with 0.02% EDTA only (in the case of E-cadherin surface expression). Surface expression levels were determined using primary antibodies, followed by fluorescence-conjugated secondary antibodies, and analysis on a FACSCanto or sorting on a FACSCalibur (Becton Dickinson).
For immunohistochemistry, cells were fixed in 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, blocked with 2% BSA, and incubated with indicated antibodies followed by fluorescently labeled secondary antibodies in combination with Hoechst nuclear staining. Preparations were mounted in Aqua-Poly/Mount solution (Polysciences Inc.) and analyzed using a Nikon TE2000 confocal microscope.
Statistical analysis
Data are presented as means ± SEM of at least three independent biological replicates unless otherwise stated. Student's t test (two-tailed) was used to compare groups.
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